As a result of confidentiality agreements, the identities from the trial members keep on being undisclosed. Eli Lilly, the pharmaceutical company powering retatrutide, declined to comment on the protocols of its ongoing trials but stated that patient safety is really a priority.Eli Lilly developed retatrutide as A part of its efforts to advance sub